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INTRODUCTION
Coccidioidomycosis  was  initially  identified  and
classified incorrectly as a protozoan species in 1892 by
Alejandro Posadas,(2) It was reclassified as a fungus in
1900(3)  but  retained  the  name  due  to  its  close
resemblance  to  the  protozoan  coccidian.  The  two
species which cause human disease, C. immitis and C.
posadasii, are named for the seriousness of the disease
(immitis, latin: not mild) and in homage to Alejandro
Posadas. Alejandro Posadas’ initial case, a 36 year old
Argentinean soldier, eventually died from the disease in
1898.  Lesions, at autopsy, were found in his lungs,
adrenals,  lymph  nodes,  liver,  peritoneum,  prostate,
spleen, and testes.(4)
Disseminated  coccidioidomycosis  is  a  regional
disease which has national importance.(5) Coccidioides
is  a  dimorphic  fungus  endemic  to  the  southwestern
United States as well as Central and South America.(6)
Outbreaks have also been described well outside the
generally accepted borders. Some are due to travel to
endemic areas(7-15), while others represent expansion
of  the  known  borders  of  Coccidioidomycosis  (16)
Coccidioidomycosis  causes  a  range  of  clinical
presentations from asymptomatic disease, a mild self-
limited  respiratory  disease  (17)  to  dissemination  to
multiple systems and organs.  Dissemination, especially
fungemia, (18-20) can lead quickly to sepsis and death.  
Coccidioidomycosisis  is  usually  acquired  via
exposure  to  dust  from  soil  containing  spores.  Once
inhaled  the  spores  take  1-3  weeks  to  germinate  and
cause  disease.  It  is  not  spread  via  human  to  human
contact  and  outbreaks  are  highly  dependent  on
environmental conditions.  Dry, hot summers after a wet
winter  and  spring,  increase  the  number  of  reported
cases.(21)  It  is  common  in  the  Southern  California
region and, in some endemic San Joaquin valley areas,
75% of the population has immunity against the fungus
as measured by skin testing (22). 
Disseminated disease is likely to be seen in certain
populations;  The  infection  and  dissemination  rate  is
much higher among Blacks and Filipinos (23).  Males
are infected more often than females (24), which may
be exposure based, but may also be related to hormonal
or genetic factors.  HIV patients (especially with CD4
counts  <  100)(25-28)  as  well  as  patients  on  chronic
immunosuppression  for  other  medical  conditions
(rheumatological and/or transplant related diseases) and
those  treated  with  immunosuppressive  chemotherapy
are  at  higher  risk  of  either  reactivation  of  a  latent
infection  or  disseminated  disease  (29-35).  Diabetes,
which does appear to increase the risk for symptomatic
infection and may increase the risk for dissemination
(36). 
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The disseminated form of Coccidioidomycosis may
present with evidence of involvement of  the skin (19,
37),  prostate  gland  (38-43),  eye  (44,  45),  bone  (46),
meninges (47-49) and liver (50-56). Splenic and hepatic
involvement,  as  diagnosed  on  autopsy,  has  been
described  previously  (4)  but  clinically  evident
hepatosplenomegaly  in  a  living  adult  patient  has  not
been widely reported.  We present a case of a healthy
adult  HIV  seronegative  patient  with  massive
hepatosplenomegaly from disseminated cocci. 
CASE PRESENTATION
The patient was an incarcerated 24 year old African
American  male  who  presented  to  the  Emergency
Department (ED) from a correctional facility where he
had served four months of his sentence.  He had been
participating in a work-release program during which
he was responsible for cleaning up camp sites, national
forest sites, and roadways, where it is suspected that he
came  into  contact  with  soil  containing  spores  of
coccidioidomycosis.
His chief complaint was anorexia and rare vomiting
for  approximately  two  months.    He  had  begun
experiencing worsening general malaise, a ten pound
weight loss and had become increasingly short of breath
with an occasional cough. 
The patient stated that he used alcohol occasionally
and  had  an  approximately  three-pack-year  history  of
smoking,  which  he  stopped  a  few  years  ago.    The
patient  also  admitted  to  drug  use  (marijuana  and
methamphetamine) before his incarceration. He had no
prior  hospital  admissions  and  had  been  in  excellent
health until two months before admission.  He took no
medications regularly and had no allergies. He denied
any recent sexual contact. Prior to his incarceration he
stated  that  he  was  in  a  stable  relationship  with  his
girlfriend.
His maternal family had sickle cell trait, but he and his
sister were negative for sickle cell trait or disease. His
paternal family history was unknown.
On initial evaluation his blood pressure was 110/60,
respiratory  rate  41,  temperature  38.3,  heart  rate  134,
saturation  98%  on  15  Liters  O2  on  a  non-rebreather
mask with bilateral crackles. His initial physical exam
was otherwise notable for an enlarged liver and spleen
with a spleen tip palpable at 8 centimeters below the
lateral rib margin.  He had two cafe-au-lait spots on his
anterior abdomen but his exam was otherwise negative.
Rectal and Guaiac exams were also negative.
His  initial  labs  were  as  follows:  Sodium  126,
potassium  5.1,  chloride  98,  bicarb  18,  BUN  25,
creatinine 1.4, glucose 89, calcium 7.7,  Phosphorus 4.3.
Hemoglobin  4.9,    hematocrit  16.1,  white  blood  cell
count 17.9, platelet count 98,000, MCV 72.  Arterial
blood gas:  pH 7.49, PCO2 24, PO2 111, bicarb 18, CO2
19.  Iron 9, iron saturation 5%.  iron binding capacity
118 with generous iron stores on bone marrow biopsy.
Bilirubin was 2.4, direct bilirubin 1.2, indirect bilirubin
1.2,  alkaline  phosphatase  192,  ALT  76,  AST  85.
Further  workup  during  his  admission  included  a
negative ELISA HIV test and his CD4 count was 384
(during his illness). His sedimentation rate was 55. A
hemoglobin  electrophoresis  was  performed  which
revealed no Hgb S, Hgb A1 90.5%, A2 3.7%, F 5.4%.
A serum protein electropheresis showed no monoclonal
region. Pneumocystis jiroveci (previously carinii) direct
fluorescent antibody was negative. Blood cultures were
initially negative on admission.  Cryptococcal antigen
was negative in a cerebrospinal fluid sample. Sputum
acid fast bacilli staining was negative and the samples
were culture negative.  Legionella urinary antigen was
negative.  
A  Computerized  tomography  (CT)  scan  showed
hepatosplenomegaly  with  a  miliary  infiltrate  in  both
organs.
He initially refused intubation but as he became more
fatigued from his tachypnea he eventually consented.
His tachycardia and tachypnea were initially thought to
be  due  to  his  severe  anemia  and  burden  of  his
underlying disease.  He was transferred to the Intensive
Care  Unit  (ICU)  where  he  progressed  to  acute
respiratory distress syndrome (ARDS).  He was initially
given  Azithromycin  500  mg  a  day,  Piperacillin/
Tazobactam  3.375  grams  IV  every  8  hours,  and
Vancomycin 1250 mg IV every 12 hours.  His initial
hemoglobin and low platelets prompted a bone marrow
biopsy  on  day  3  which  showed  Coccidioidomycosis
spherules. He also had a positive endotracheal aspirate
for  methicillin  sensitive  staph  aureus.  When  the
spherules were described on the bone marrow aspirate,
and confirmed with serological testing, he was started
on Fluconazole 600 mg every day and given Nafcillin 2
grams  IV  every  4  hours.    Fungal  blood  cultures
eventually grew coccidioides. When he did not improve
after 4 days he was switched to amphotericin for one
dose  then  to  liposomal  amphotericin  which  caused
acute renal failure. (BUN 77, Cr 3.5).  His course was
also  complicated  by  a  ventilator  associated
pseudomonas  pneumonia  which  was  treated  with
Piperacillin/Tazobactam 2.25 grams every 6 hours and
Levofloxacin 500 mg IV every 6 hours.  His anemia was
recalcitrant to multiple transfusions and he had minor
bleeding from multiple sites.
The  patient  developed  a  board-like  abdomen  and  a
perforated  viscus  was  suspected.  An  exploratory
laparotomy  was  performed  on  hospital  day  13.    No
perforation  was  identified  but  the  spleen  and  liver
appeared irregular and were infiltrated with large fungal16 McGill Journal of Medicine 2009
colonies  on  biopsy.  Given  the  massive  splenic
involvement  which  was  felt  to  be  compressing  his
diaphragm  and  affecting  his  pulmonary  function,  a
splenectomy  was  performed.  His  spleen  is  pictured
below (Figures 1-3).  It measured 25 cm by 18 cm by
14.5  cm,  weighed  almost  9  pounds  and  had  visible
coccidioidomycosis colonies on macroscopic exam. The
pathology slides also confirmed colonies of coccidioides
(Figures  4-5).  Despite  antibiotic  and  antifungal
treatment, after a total of 18 days he developed a cardiac
arrhythmia and died on ventilatory support.
DISCUSSION
Splenomegaly  is  an  uncommon  finding  in
disseminated cocci, especially in an immunocompetent
person.  Our review of the literature was unable to find
any  previously  reported  cases  of  clinically  evident
splenomegally in an immunompetent host. We hope that
other similar cases will continue to be reported so that
further insight into this disease process may be gleaned.
This case highlights many of the problems commonly
encountered  in  patients  with  Coccidioidomycosis
infections:  delay  to  diagnosis,  low  suspicion  with
diagnosis  suggested  from  peripheral  tests,  and
seriousness  in  African  American  males.    The
uncommon  features  are  also  notable;  his  rapid
progression  to ARDS,  sepsis  and  death,  his  negative
HIV ELISA and his relatively appropriate CD4 count
along with no significant past medical history are not
commonly encountered in a case this severe.  This case
highlights  the  importance  of  considering
Coccidioidomycosis and other mycotic diseases when
presented  with  a  patient  in  respiratory  failure,  even
when they are not immunosuppresed.  
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